home

LATEST ONCOPRESCRIBE UPDATES

• ADCETRIS® Improves Overall Survival in Stage III or IV Hodgkin’s Lymphoma

• Late Breaking Abstract – ASCO 2022: Improved Distant Metastasis-Free Survival with Adjuvant KEYTRUDA® in High Risk Stage II Melanoma

• Late Breaking Abstract – ASCO 2022: RUBRACA® Monotherapy as Maintenance Treatment in Newly Diagnosed Ovarian Cancer

• Late Breaking Abstract – ASCO 2022: Nimotuzumab Significantly Improves Overall Survival in K-Ras Wild-Type Advanced Pancreatic Cancer

• Late Breaking Abstract – ASCO 2022: FOLFOXIRI Plus Bevacizumab in Unresectable Colorectal Cancer with Liver Metastases

• Late Breaking Abstract – ASCO 2022: RVd Plus Autologous Stem Cell Transplantation and REVLIMID® Maintenance Improves PFS in Multiple Myeloma

• Late Breaking Abstract – ASCO 2022: ENHERTU® for HER2-Low Advanced Breast Cancer

• Screening for Pancreatic Cancer Results in Early Detection and Improved Overall Survival

SHOW MORE

FDA
Approvals

Meeting
Updates

Hem/Onc
Updates

Symptom
Management

NEW REGIMENS ADDED

Research Regimens

• TIBSOVO® - for Acute Myeloid Leukemia

• KEYTRUDA® - for Malignant Melanoma

• TECENTRIQ® and ABRAXANE® - for Breast Cancer

• KEYTRUDA® plus INLYTA® - for Renal Cancer

• PARAPLATIN® and VEPESID® with TECENTRIQ® - for Small Cell Lung Cancer

Curbside Consultation

Biomarker Testing in NSCLC-Special Issue

Immuno-Oncology

Precision Oncology

• COVID-19 Associated Coagulopathy: Diagnosis and Management

• TTP, HUS and aHUS: Different diseases – Different treatments

• HER2 Testing in Breast Cancer American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update

• Dual Inhibition Improves Outcomes for Patients with BRAF-Mutated Colorectal Tumors

• FDA Approves ENDARI®, A New Treatment for Sickle Cell Disease

SHOW MORE